Lung sparing in MR-guided non-adaptive SBRT treatment of peripheral lung tumors

被引:0
|
作者
Lee, Ho Young [1 ]
Lee, Grace [1 ]
Ferguson, Dianne [1 ]
Hsu, Shu-Hui [1 ]
Hu, Yue-Houng [1 ]
Huynh, Elizabeth [2 ]
Sudhyadhom, Atchar [1 ]
Williams, Christopher L. [1 ]
Cagney, Daniel N. [3 ]
Fitzgerald, Kelly J. [1 ]
Kann, Benjamin H. [1 ]
Kozono, David [1 ]
Leeman, Jonathan E. [1 ]
Mak, Raymond H. [1 ]
Han, Zhaohui [1 ]
机构
[1] Harvard Med Sch, Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA
[2] London Reg Canc Program, Dept Radiat Oncol, London, ON, Canada
[3] Mater Private Network, Radiotherapy Dept, Dublin, Ireland
来源
BIOMEDICAL PHYSICS & ENGINEERING EXPRESS | 2024年 / 10卷 / 04期
关键词
MR linac; MRgSBRT; breath-hold; peripheral lung cancer; real-time gating; STEREOTACTIC BODY RADIOTHERAPY; ADAPTIVE RADIATION-THERAPY; PNEUMONITIS; STRATEGIES; CANCER;
D O I
10.1088/2057-1976/ad567d
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective. We aim to: (1) quantify the benefits of lung sparing using non-adaptive magnetic resonance guided stereotactic body radiotherapy (MRgSBRT) with advanced motion management for peripheral lung cancers compared to conventional x-ray guided SBRT (ConvSBRT); (2) establish a practical decision-making guidance metric to assist a clinician in selecting the appropriate treatment modality. Approach. Eleven patients with peripheral lung cancer who underwent breath-hold, gated MRgSBRT on an MR-guided linear accelerator (MR linac) were studied. Four-dimensional computed tomography (4DCT)-based retrospective planning using an internal target volume (ITV) was performed to simulate ConvSBRT, which were evaluated against the original MRgSBRT plans. Metrics analyzed included planning target volume (PTV) coverage, various lung metrics and the generalized equivalent unform dose (gEUD). A dosimetric predictor for achievable lung metrics was derived to assist future patient triage across modalities. Main results. PTV coverage was high (median V100% > 98%) and comparable for both modalities. MRgSBRT had significantly lower lung doses as measured by V20 (median 3.2% versus 4.2%), mean lung dose (median 3.3 Gy versus 3.8 Gy) and gEUD. Breath-hold, gated MRgSBRT resulted in an average reduction of 47% in PTV volume and an average increase of 19% in lung volume. Strong correlation existed between lung metrics and the ratio of PTV to lung volumes (R-PTV/Lungs) for both modalities, indicating that R-PTV/Lungs may serve as a good predictor for achievable lung metrics without the need for pre-planning. A threshold value of R-PTV/Lungs < 0.035 is suggested to achieve V20 < 10% using ConvSBRT. MRgSBRT should otherwise be considered if the threshold cannot be met. Significance. The benefits of lung sparing using MRgSBRT were quantified for peripheral lung tumors; R-PTV/Lungs was found to be an effective predictor for achievable lung metrics across modalities. R-PTV/Lungs can assist a clinician in selecting the appropriate modality without the need for labor-intensive pre-planning, which has significant practical benefit for a busy clinic.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Mitigation on bowel loops daily variations by 1.5-T MR-guided daily-adaptive SBRT for abdomino-pelvic lymph-nodal oligometastases
    Cuccia, Francesco
    Rigo, Michele
    Gurrera, Davide
    Nicosia, Luca
    Mazzola, Rosario
    Figlia, Vanessa
    Giaj-Levra, Niccolo
    Ricchetti, Francesco
    Attina, Giorgio
    Pastorello, Edoardo
    De Simone, Antonio
    Naccarato, Stefania
    Sicignano, Gianluisa
    Ruggieri, Ruggero
    Alongi, Filippo
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (11) : 3269 - 3277
  • [42] Mitigation on bowel loops daily variations by 1.5-T MR-guided daily-adaptive SBRT for abdomino-pelvic lymph-nodal oligometastases
    Francesco Cuccia
    Michele Rigo
    Davide Gurrera
    Luca Nicosia
    Rosario Mazzola
    Vanessa Figlia
    Niccolò Giaj-Levra
    Francesco Ricchetti
    Giorgio Attinà
    Edoardo Pastorello
    Antonio De Simone
    Stefania Naccarato
    Gianluisa Sicignano
    Ruggero Ruggieri
    Filippo Alongi
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 3269 - 3277
  • [43] Clinical outcome of image-guided adaptive radiotherapy in the treatment of lung cancer patients
    Tvilum, Marie
    Khalil, Azza A.
    Moller, Ditte S.
    Hoffmann, Lone
    Knap, Marianne M.
    ACTA ONCOLOGICA, 2015, 54 (09) : 1430 - 1437
  • [44] First experience of autonomous, un-supervised treatment planning integrated in adaptive MR-guided radiotherapy and delivered to a patient with prostate cancer
    Kuenzel, Luise A.
    Nachbar, Marcel
    Hagmueller, Markus
    Gani, Cihan
    Boeke, Simon
    Zips, Daniel
    Thorwarth, Daniela
    RADIOTHERAPY AND ONCOLOGY, 2021, 159 : 197 - 201
  • [45] Issues and prospects of image-guided thermal ablation in the treatment of primary and metastatic lung tumors
    Wang, Meixiang
    Wei, Zhigang
    Ye, Xin
    THORACIC CANCER, 2023, 14 (01) : 110 - 115
  • [46] The first patient treatment of electromagnetic-guided real time adaptive radiotherapy using MLC tracking for lung SABR
    Booth, Jeremy T.
    Caillet, Vincent
    Hardcastle, Nicholas
    O'Brien, Ricky
    Szymura, Kathryn
    Crasta, Charlene
    Harris, Benjamin
    Haddad, Carol
    Eade, Thomas
    Keall, Paul J.
    RADIOTHERAPY AND ONCOLOGY, 2016, 121 (01) : 19 - 25
  • [47] Real-time motion monitoring using orthogonal cine MRI during MR-guided adaptive radiation therapy for abdominal tumors on 1.5T MR-Linac
    Jassar, Hassan
    Tai, An
    Chen, Xinfeng
    Keiper, Timothy D. D.
    Paulson, Eric
    Lathuiliere, Fabienne
    Beriault, Silvain
    Hebert, Francois
    Savard, Laurence
    Cooper, David T. T.
    Cloake, Sneha
    Li, X. Allen
    MEDICAL PHYSICS, 2023, 50 (05) : 3103 - 3116
  • [48] MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open randomized, multicentric, parallel group clinical trial (MASPAC)
    M. Pavic
    M. Niyazi
    L. Wilke
    S. Corradini
    M. Vornhülz
    U. Mansmann
    A. Al Tawil
    R. Fritsch
    J. Hörner-Rieber
    J. Debus
    M. Guckenberger
    C. Belka
    J. Mayerle
    G. Beyer
    Radiation Oncology, 17
  • [49] SBRT Treatment of Metachronous Small-Cell and Non-Small-Cell Lung Carcinomas in a Patient with Severe COPD
    Duimering, Adele
    Gabos, Zsolt
    Debenham, Brock
    CUREUS, 2015, 7 (12):
  • [50] Stereotactic body radiotherapy (SBRT) for the treatment of inoperable stage I non-small cell lung cancer patients
    Ceniceros, L.
    Aristu, J.
    Castanon, E.
    Rolfo, C.
    Legaspi, J.
    Olarte, A.
    Valtuena, G.
    Moreno, M.
    Gil-Bazo, I.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2016, 18 (03): : 259 - 268